Senior Director, Head of Early Development Regulatory Affairs

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company is looking for a Senior Director, Head of Early Development Regulatory Affairs to lead global regulatory strategy for early-stage programs.

Requirements

• 8 years of regulatory experience in biotech or pharmaceutical industry required.
• Significant experience leading early development programs (IND-enabling through Phase 2).
• Demonstrated success leading global health authority interactions.
• Experience building or scaling regulatory processes in a growing organization.
• Ability to influence and partner with senior stakeholders.

Benefits

• Competitive cash compensation
• Robust equity awards
• Strong benefits
• Significant learning and development opportunities